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Heme is a ligand for the human nuclear receptors (NR) REV-ERBa and REV-ERBb, which are transcriptional repressors
that play important roles in circadian rhythm, lipid and glucose metabolism, and diseases such as diabetes,
atherosclerosis, inflammation, and cancer. Here we show that transcription repression mediated by heme-bound REV-
ERBs is reversed by the addition of nitric oxide (NO), and that the heme and NO effects are mediated by the C-terminal
ligand-binding domain (LBD). A 1.9 A ˚ crystal structure of the REV-ERBb LBD, in complex with the oxidized Fe(III) form of
heme, shows that heme binds in a prototypical NR ligand-binding pocket, where the heme iron is coordinately bound
by histidine 568 and cysteine 384. Under reducing conditions, spectroscopic studies of the heme-REV-ERBb complex
reveal that the Fe(II) form of the LBD transitions between penta-coordinated and hexa-coordinated structural states,
neither of which possess the Cys384 bond observed in the oxidized state. In addition, the Fe(II) LBD is also able to bind
either NO or CO, revealing a total of at least six structural states of the protein. The binding of known co-repressors is
shown to be highly dependent upon these various liganded states. REV-ERBs are thus highly dynamic receptors that
are responsive not only to heme, but also to redox and gas. Taken together, these findings suggest new mechanisms
for the systemic coordination of molecular clocks and metabolism. They also raise the possibility for gas-based
therapies for the many disorders associated with REV-ERB biological functions.
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Introduction
The closely related REV-ERBa and REV-ERBb proteins
generally act as transcriptional repressors, either on their
own, by recruiting co-repressor proteins [1–3], or by
competing with the Retinoid-related Orphan Receptors
(RORs) a, b,o rc for the same DNA binding sites [4–6].
Physiologically, the REV-ERB proteins play a number of
diverse and important roles ranging from the control of
circadian biology to the homeostasis of lipids. REV-ERBa and
b directly regulate circadian rhythm, both in the brain, and in
peripheral tissues, by targeting the circadian clock genes
Bmal1 and clock [6–11]. Regulation of lipid metabolism and
stimulation of adipogenesis by the REV-ERBs is mediated in
part through repression of the apolipoprotein A1 (ApoA1)
and apolipoprotein C3 (ApoCIII) gene promoters, which play
major roles in cholesterol metabolism [12–14]. REV-ERBs also
control inﬂammatory responses by inducing nuclear factor
kappa-light-chain-enhancer of activated B cells (NFjB),
interleukin-6 (IL6), and cyclooxygenase2 (COX2) expression,
and by repressing IjBa expression [15,16]. In the liver, REV-
ERBs also help regulate gluconeogenesis, consistent with an
overall role in energy storage and conservation [17].
In Drosophila, the REV-ERB homologue, Ecdysone-induced
protein 75 (E75) is best known for its role in developmental
timing, acting together with the ROR orthologue Drosophila
Hormone Receptor 3 (DHR3) to control ecdysone-induced
molting, pupariation, and eclosion [18]. To perform these
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PLoS BIOLOGYfunctions, E75 appears to require heme as a requisite ligand,
bound presumably within its ligand-binding domain (LBD)
ligand pocket. E75 is not stable in the absence of heme, nor
does the bound heme dissociate readily, suggesting that heme
is an obligate component of E75. Interestingly, the presence
of heme allows E75 to also bind the diatomic gases nitric
oxide (NO) and carbon monoxide (CO), which function to
reverse E75-mediated transcription repression [19]. The REV-
ERBs also bind heme but, unlike E75, the heme can readily
dissociate from the REV-ERBs, and this reversible binding
regulates REV-ERB transcription activity [17,20]. The REV-
ERB LBDs do not appear to share the ability to bind gases or
to respond to redox [20], raising the possibility that E75 and
REV-ERBs have evolved two different ways to exploit heme-
binding.
The structural basis for heme binding in REV-ERB
proteins, and heme and gas binding in E75, is unknown,
although mutagenesis and transcription studies have impli-
cated conserved histidine and cysteine residues in heme
binding. A crystal structure of the REV-ERBb LBD in the
absence of heme has revealed a classic nuclear receptor (NR)
fold, but the mechanisms of heme binding could not be
deduced from the structure, because the conserved histidine
residue points away from the putative ligand-binding pocket
and the conserved cysteine residue was not present in the
construct that generated the structure. Moreover, the
putative pocket is fully occupied by hydrophobic side chains
[21]. The extensive structural similarities between the REV-
ERB and E75 LBDs coupled with the apparent mechanistic
differences prompted us to explore more deeply the basis for
both heme binding and the potential for gas regulation.
The potential involvement of gases in circadian rhythm has
been noted in physiological studies for some time, but the
molecular mechanisms only began to emerge with the ﬁnding
that Neuronal PAS domain protein (NPAS2), a CLOCK
protein analog, is a hemoprotein [22–24]. NPAS2 and CLOCK
heterodimerize with Brain and Muscle Arnt-like protein-1
(BMAL1) to activate transcription of various genes, including
the molecular clock components Period, Cryptochrome, and
Rev-erb [25–29]. The binding of CO to the NPAS2-heme
complex, in vitro, inhibits its binding to BMAL1 and DNA
binding [23]. Using transcription assays from native and
model promoters in cells, we report that the REV-ERBs are
also gas-binding components of the molecular clock and that
gas and redox state modulate the structure and function of
the REV-ERB LBDs. Using crystallography and spectroscopy,
we determined the structure of the heme-bound REV-ERBb
LBD from which we are able to propose a model for heme
and gas binding.
Results
Heme Binding to REV-ERB LBD Is Reversible
Overexpression of either of the REV-ERB LBDs in
Escherichia coli produces apo forms of the repressors. The
heme-bound form is produced only if the culture medium is
supplemented with hemin (Figure S1). While REV-ERBs
expressed with and without hemin supplementation appear
to be equally abundant and soluble (Figure S1), they differ
strikingly in color, with the heme-bound form intensely red,
and the apo form colorless. Incubation of either puriﬁed
REV-ERBa or b apo LBD with hemin in solution, results in
full heme occupancy within seconds or less (unpublished
data), while washing the heme-bound LBDs with buffer
lacking heme leads to a much slower release of the bound
heme (T1/2 ;13–16 h; Figure S2). Overall a Kd of approx-
imately 6 lM was observed (unpublished data). Thus, unlike
E75, where heme appears to act as a requisite structural
component, in the REV-ERBs it can function potentially as a
reversible ligand.
Heme Is Coordinately Bound to Alternative His and Cys
Residues
Spectroscopic evidence has suggested that the coordina-
tion of heme in E75 involves a cysteine residue, and
mutagenesis has further suggested that this thiolate bond is
contributed by Cys396 (JR, unpublished data) [30], which
corresponds to Cys418 in REV-ERBa and Cys384 in REV-
ERBb. Mutagenesis of E75 has also suggested that the second
protein-heme coordinate bond is provided by the side chain
of His574 (His602 in REV-ERBa; His568 in REV-ERBb)
[19,30]. Consistent with this ﬁnding, the mutation of His602
of REV-ERBa (His568 in REV-ERBb) to phenylalanine
essentially eliminates heme binding [17,20]. Our mutagenesis
of REV-ERBb conﬁrms that Cys384 and His568 are both key
mediators of heme binding (Figure 1), although the His568
mutant of REV-ERBb did maintain some heme-binding
Figure 1. Mutagenesis of REV-ERBb Heme-Binding Residues
As detemined by measurement of construct c absorption peaks (419
nm), mutation of heme binding residues reduces, but does not abolish
heme binding.
doi:10.1371/journal.pbio.1000043.g001
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Author Summary
Much of human biology, such as sleeping, eating, and even the
prevalence of heart attacks, occurs in daily cycles. These cycles are
orchestrated by a master ‘‘clock’’ located in the brain. The basic
components of this clock are proteins that control the expression of
important genes. In this study, we analyze one of these regulatory
proteins, named REV-ERB, and show that it is regulated by the
combination of heme and nitric oxide gas, both of which are
important regulators of human physiology. By determining the 3-D
structure of the REV-ERB protein, we were able to uncover clues as
to how this regulation occurs. REV-ERB belongs to a protein family
called nuclear hormone receptors, which are known to be excellent
drug targets. Thus, this paper opens the door to possible gas-based
therapies for diseases known to involve REV-ERB, such as diabetes,
atherosclerosis, inflammation, and cancer.activity compared with the His602 mutant of REV-ERBa
[17,20]. In our REV-ERBb analysis, the levels of bound heme
decrease in each of the puriﬁed Cys384 and His568 mutant
proteins, but neither of the single mutations to alanine, nor
the Cys384A/His568A double mutation, completely eliminate
heme binding (Figure 1). These differences may be attribut-
able to the different choices for amino acid substitution (Ala
versus Phe), or other differences between the two proteins.
Thus, residues in addition to these particular Cys and His
residues must also contribute to heme binding.
Coordinate Bonds Change as a Function of Redox State
The structures of other heme-containing transcription
factors are modulated by redox state [23,31–33]. To inves-
tigate the effects of redox state on the interaction of REV-
ERBs with heme, we subjected the heme-bound proteins to
electronic absorption spectral analysis. The heme in coor-
dinately bound proteins absorbs at characteristic wave-
lengths, producing what are referred to as a, b, and c (or
Soret) heme absorption peaks. The existence, positions, and
sizes of these peaks provide insight into the oxidation and
spin states of the iron center and the number and types of
coordinate bonds formed.
The oxidized Fe(III) REV-ERBb LBD yielded an absorption
spectrum (Figure 2A) that was almost identical to those
produced by aerobically puriﬁed Drosophila E75 [19] and the
bacterial thiolate-heme Fe(III)-containing transcription fac-
tor CooA [31]. All three proteins exhibit characteristic a
(;575 nm, shoulder), b (542 nm), and c (419 nm) absorption
peaks as well as a prominent d-band (359 nm); altogether,
these are indicative of a hexa-coordinated heme bound to at
least one thiolate (e.g., Cys) group [30]. Upon subjecting the
REV-ERBb LBD to the reducing agent sodium hydrosulphite
(dithionite), the resultant shifts in absorption peaks (Figure
2B) indicate reduction of the iron center from Fe(III) to
Fe(II), and loss of the thiolate coordinate bond (diagrammed
in Figure 3); this reduction is seen most readily by the loss of
the d-band (359 nm). We have also reported elsewhere [34],
using magnetic circular dichroism and resonance Raman
spectroscopy, that reduction of the REV-ERBb iron center
appears to yield both a 5-coordinated system, with a single
neutral residue coordinate bond (e.g., His or Pro), as well as a
6-coordinated system with two neutral residue bonds (Figure
3). Thus, the reduced REV-ERB-heme complex comprises at
least two structural states in which the heme-coordinating
amino acid side chains change. This form of redox-regulated
coordinate bond switching is not unique to REV-ERBs. For
example, similar side chain-switching states have been
observed in CooA (Cys
75 to His
77), a bacterial CO-responsive
heme thiolate protein transcription factor [35–37], and in
Figure 2. REV-ERBb Contains Heme and Can Be Reduced and Binds Diatomic Gases In Vitro
(A) Electronic absorption spectrum of 0.5 mg/ml recombinant REV-ERBb aerobically purified from bacteria (supplemented with 50 mg/l hemin during
growth).
(B) REV-ERBb plus 2 mM sodium hydrosulphite.
(C) Reduced REV-ERBb plus 100 lM CO.
(D) Reduced REV-ERBb plus 100 lM NO. The region from 500 nm to 620 nm is inset and magnified for presentation of the a and b peaks. The analogous
spectra for REV-ERBa were similar.
doi:10.1371/journal.pbio.1000043.g002
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170 to His
171), whose axial coordinate bonds are
also different in the Fe(III) and Fe(II) states [23,33,38]. In these
transcription factors, these redox-dependent structural
changes also result in functional changes for their host
proteins. Redox was also shown to modulate E75 coordinate
bonding and function [19], but it remains to be seen if the
redox-dependent structural changes in the REV-ERBs also
have analogous functional consequences.
REV-ERB-Heme Proteins Can Bind NO and CO Gases
As pointed out earlier, many coordinately bound heme
proteins, including proteins such as hemoglobin, cyto-
chromes, and the transcription factors CooA and NPAS2,
have the added ability to bind gases [23,31,37]. This ability is
also the case for the REV-ERB insect orthologue E75 [19]. As a
ﬁrst step in assessing the gas-binding potential of REV-ERB
proteins, the reduced REV-ERBb LBD was incubated with CO
or NO gas and analyzed for characteristic changes in the
electronic absorption spectra. The altered electronic absorp-
tion proﬁles conﬁrm direct binding of both diatomic gases to
the heme-bound forms of both REV-ERB LBDs. When
incubated with either NO or CO, the reduced (but not
oxidized) REV-ERBb LBD exhibits classic shifts in the
absorption peaks (Figure 2C, 2D) similar to those seen in
other gas-bound hemoproteins [31,39,40]. More detailed
studies of the heme in REV-ERB LBDs [34] have shown that
the NO and CO gases bind opposite to a neutral side chain in
a 6-coordinated state (Figure 3). Thus, the heme-binding data
reported previously [17,20] and the spectroscopic data
reported here and in Marvin et al. [34] reveal that REV-ERBs
comprise modular ligand systems that can adopt a minimum
of six different LBD structural states (Figure 3), each of which
has the potential for distinct functional interactions, tran-
scriptional outputs, and biological roles.
NO Reverses REV-ERB Mediated Repression In Vivo
Among the many genes targeted for repression by the REV-
ERB proteins are their own genes and the clock gene Bmal1.
To test the effects of NO or CO on the activities of REV-ERBa
and b in vivo we monitored transcription levels of the
endogenous Bmal1 and Rev-erb genes in human embryonic
kidney (HEK) 293T and hepatocellular carcinoma (HepG2)
cells in response to gas. We ﬁrst conﬁrmed that transcription
from these genes is regulated by the REV-ERBs by measuring
Figure 3. REV-ERBs Can Assume at Least Six Different Heme Binding States
In the absence of heme, the ligand pocket of REV-ERBs is stabilized with the side chains of core hydrophobic residues. Heme can bind to the REV-ERBs in
either reduced Fe(II) or oxidized Fe(III) states, and while reduced is in a five or six coordinate state. REV-ERBs also bind the diatomic gases CO and NO
through the creation of a coordinate bond between the Fe(II) center of heme.
doi:10.1371/journal.pbio.1000043.g003
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small interfering RNA (siRNA). Figure 4A shows that each of
the Rev-erb siRNAs speciﬁcally targets its corresponding Rev-
erb gene. As expected, the knock-down of either Rev-erb gene
results in an increase in Bmal1 expression (1.5–2-fold; Figure
4A), due presumably to derepression of ROR-mediated
transcriptional activation. Effects were readily observed
within 12 h of siRNA treatment, and peaked at 72 h post-
treatment.
We then asked whether NO, supplied by the chemical
donor diethylenetriamine/NO (Deta/NO), relieves REV-ERB-
mediated repression of the endogenous Bmal1, Rev-erba, and
Rev-erbb genes. Addition of Deta/NO increased levels of
Bmal1, Rev-erba, and Rev-erbb mRNAs by 2–3-fold (Figure
4B). The addition of Li
2þ, which has been shown to cause
REV-ERB degradation via inhibition of Glycogen Synthase
Kinase-3 b (GSK3b) kinase-mediated phosphorylation [41],
led to a similar derepression of the endogenous Rev-erb and
Bmal1 target genes. Importantly, combining NO and siRNA
treatments did not have additive effects, suggesting that NO
acts via derepression of the REV-ERBs and not via a parallel
pathway (Fig 4C). NO-dependent transcription was also
observed in HepG2 cells, with the exception that NO-
mediated upregulation of ROR/Rev-erb target gene expres-
sion was only ;2-fold (Figure S3). This may reﬂect lower
levels of available heme in this cell type, as heme levels vary
signiﬁcantly in different cell types and in other cell states
[42,43]. Analogous studies conducted in the presence of 500
ppm CO, yielded only modest changes in REV-ERB target
gene expression (unpublished data). This minimal response
may be due to differences in afﬁnity or effectiveness between
NO and CO in cells, or to differences in the effectiveness of
the different gas delivery protocols used (see Methods).
To provide evidence that NO acts as a direct regulator of
heme-bound REV-ERB proteins, the LBDs of either REV-
ERBa or b were fused to the DNA-binding domain of yeast
GAL4, and their activities tested using a luciferase reporter
regulated by a thymidine kinase promoter containing up-
stream activating sequences (UAS)GAL4 binding sites. As
expected, co-transfection of the GAL4-REV-ERBa or GAL4-
REV-ERBb fusion proteins repressed transcription driven by
the UAS-containing thymidine kinase promoter (Figure 4D).
This repression was reversed by greater than 3.5-fold by the
addition of either of two NO donors, Deta/NO (Figure 4D) or
Figure 4. REV-ERBa and b-Mediated Repression Is Relieved by a NO Donor
(A) Endogenous mRNA levels of Bmal1 and Rev-erba and b in control and Rev-erba and b siRNA treatments.
(B) Bmal1 and Rev-erba and b gene expression following treatment with either 300 lM Deta/NO or 20 mM LiCl.
(C) Comparison of Bmal1 gene expression levels in control, Deta/NO- and siRNA-treated cells.
(D) Transient transfection of 293T cells with GAL4-REV-ERBa or GAL4-REV-ERBb results in repression of the UASGAL4-containing luciferase reporter.
Treatment of the cells with Deta/NO leads to a 3-fold derepression of luciferase expression. All experiments were performed in triplicate, with the error
bars showing sample to sample variation. Experimental data shown are representative of a minimum of three repeats under the same conditions.
doi:10.1371/journal.pbio.1000043.g004
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ta), suggesting that the REV-ERBs are direct targets of NO. As
earlier, similar studies with 750–2,000 ppm CO had a more
modest effect (;15% of NO effect; unpublished data). In
summary, both REV-ERB proteins are transcriptional re-
pressors whose activities can be reversed by NO binding.
Effects of Gases on REV-ERB Co-Repressor Binding
To determine if the heme and gas effects on REV-ERB
activity might be attributable to the recruitment of co-
repressor proteins, GAL4-REV-ERBa and GAL4-REV-ERBb
fusion proteins were co-transfected with full-length co-
repressor expression constructs into 293T cells. As expected,
addition of the known REV-ERB co-repressor Nuclear
Receptor Co-repressor (NCOR) to GAL4-REV-ERB trans-
fection assays increases repression by 2–3-fold. Similar results
were obtained by coexpression with another co-repressor,
Receptor Interaction Protein 140 (RIP140), which has not
been previously tested for REV-ERB binding (Figure 5A, 5B).
This augmented NCOR or RIP140-mediated repression is
reversed by the addition of Deta/NO (Figure 5A, 5B). Similar
reductions in Gal4-REV-ERB/co-repressor mediated repres-
sion were obtained by treating the transfected cells with
valproic acid, which is an inhibitor of the histone deacetylases
that are recruited by NCOR and RIP140 [44–46]. We conclude
that NO signaling reduces REV-ERB repression activity, at
least in part, by overcoming the recruitment or activities of
these co-repressors.
The effects of heme-binding on REV-ERB function are
unclear. Previous studies have shown that the availability of
heme negatively affects the ability of REV-ERB proteins to
bind co-repressor peptides in vitro but is required for the
REV-ERB proteins to interact functionally with co-repressors
in vivo [17,20]. To explain this ﬁnding, it has been suggested
that co-repressor interactions in vivo must be modulated by
interactions or conditions that are not reﬂected in experi-
ments with puriﬁed components. To test if the in vitro
interactions could be inﬂuenced by gas, we used ﬂuorescence
polarization to follow the recruitment of peptides corre-
sponding to the LXXI/HIXXXI/L interaction domain I (IDI) of
NCOR (Figure 6) and Silencing Mediator for Retinoid and
Thyroid hormone receptor (SMRT) (unpublished data) in the
absence and presence of heme and gas. As expected, based on
the previous study, both peptides interact speciﬁcally with the
REV-ERBa and b LBDs (Figure 6), and the addition of heme
acts negatively on co-repressor peptide binding. As might
also be expected, only the heme-bound form of the REV-ERB
LBDs are responsive to the addition of NO gas (Figure 6A–6C
and unpublished data). As with heme binding though, this
effect is the opposite of that which occurs in vivo, with NO
acting to increase co-repressor peptide recruitment, rather
than blocking it. We can only conclude, as did Yin et al. [17],
that interactions or conditions that exist in the cell, are not
reﬂected in the in vitro system.
Structural Analysis of REV-ERBb Bound with Heme
To shed light on the structural basis of heme, gas, and
redox regulation, we crystallized the REV-ERBb LBD in the
heme-bound state. The formation of well-ordered crystals
required the addition of trypsin to the crystallization solution
[47]. Two identical structures were obtained using constructs
comprising either the complete LBD (residues 212–579) or
the LBD with an internal deletion (residues 241–579 D 275–
357). Both 1.9 A ˚ resolution structures include a-helices 3–11,
(residues 381–576; REV-ERBb381–576), which is slightly larger
than the fragment used to derive the unliganded LBD
structure [21]. Both of the crystals were obtained under
nonreducing conditions.
The two REV-ERBb381–576 Fe(III) heme structures verify
that the heme-binding pocket is in fact present at the same
position as ligand-binding pockets observed in other NR
family members (Figure 7B). As predicted by the mutagenesis
and spectroscopic analyses for the oxidized state of REV-ERB,
a single heme molecule is hexa-coordinated within the pocket
by Cys384 and His568 side chains. As mentioned above,
Cys384 was not included in the previously published
unliganded receptor structure constructs [21].
The structural changes that facilitate heme binding are
conﬁned primarily to helices 3, 7, and 11. In the absence of
heme, helix 3 breaks at Pro411 allowing its N-terminal
portion to move into the unliganded pocket (Figure 7A) [21].
A number of aromatic residues from this helix face into the
pocket, contributing substantially to the hydrophobic core
that stabilizes the unliganded structure. In the presence of
Figure 5. GAL4-REV-ERBa (A) and GAL4-REV-ERBb (B)-Mediated Repression Is Augmented by Co-transfection with Equimolar Amounts (370 fmol/well)
of Full-Length NCOR or RIP140 Co-repressors
Repression, in all cases, is significantly relieved by the addition of Deta/NO. The averages from triplicate experiments are presented as relative luciferase
activity.
doi:10.1371/journal.pbio.1000043.g005
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half (Ca atom Gly398) 16.4 A ˚ away from its position in the
unliganded structure (Figure 7B). Although helix 7 shifts in a
less dramatic manner, the 3.0-A ˚ movement (Ca atom Leu482)
further increases the pocket volume. The movement of
residues 480–483, in particular, allows heme and its propio-
nate side chains to assume their observed planar orientation
(Figure 7C). In the absence of heme, helix 11 shields the
hydrophobic core by bridging helices 10 and 3. To facilitate
heme binding, it also undergoes a major conformational
change, swinging its C terminus (Ca atom Leu576) 15 A ˚ away
from the ligand-binding pocket, forming a gently curving,
uninterrupted a-helix that covers the ligand pocket (Figure
7A, 7B).
The unprecedented formation of LBD-ligand coordinate
bonds involves some equally novel and elegant structural
changes. First, the imidazole side chain of His568 makes a
;1208 rotation around the axis of the helix to allow bonding
with the Fe(III) heme center (Figure 7D, 7E). Cys384, the other
coordinate bond-forming residue in this Fe(III) structure,
derives from a ﬂexible loop N-terminal to helix 3, which does
not appear in the apo structure (Figure 7D, 7E). In addition to
opening the pocket and correctly positioning the two heme-
coordinating residues, the newly positioned helices and loop
also help to shield the hydrophobic heme moiety from the
solvent, with only 8% (66 A ˚ 2) of the ligand exposed. This value
falls well within the expected normal range of 1%–28% for
hemoproteins [48].
Figure 6. REV-ERB Binding of NCOR Peptide Is Dependent on Heme and NO Ligands
Fluorescence polarization titration curves for the binding of 110 nM NCOR peptide to apo (dashed line) or heme-bound (solid line) REV-ERBa (A) and b
(B) LBDs. Greater mP values indicate increased binding of the peptide to REV-ERBs. As expected, the nature of REV-ERB LBD binding of NCOR peptide is
dependent on heme and in the heme-bound state are responsive to NO gas.
(C) Calculated Kd values.
doi:10.1371/journal.pbio.1000043.g006
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stabilize heme binding via van der Waal interactions. Within
4A ˚ of the heme moiety are 25 residues (Table S1) derived
from ﬁve different regions of the REV-ERBb secondary
structure (H3, H5, H7, and H11, and loop N-terminal to H3).
The majority of these residues form the core of the apo-
structure [21], and must swing out and away to facilitate heme
binding (Figure 8A). In other hemoproteins the residues
forming hydrophobic heme contacts include Ile, Leu, Val,
Phe, Trp, and Tyr [48]. The REV-ERBb pocket is also enriched
with these residues, along with six phenlyalanines (Table S1).
With two exceptions, all of these residues are conserved in
REV-ERBa and among all the vertebrate REV-ERBb ortho-
logues. Although these contacts occur all around the heme
ligand, Trp402, Phe405, and Phe454 are striking examples of
how van der Waal radii of the protein side chains and heme
can interlock (Figure 8A). Taken together, these precisely
ﬁtted hydrophobic contacts must contribute signiﬁcantly to
the strength and speciﬁcity of heme binding.
Aside from Cys384 and His568, the only other polar
residues within 4 A ˚ of heme are His381 and Glu571, and
while at this point their role is undetermined, their presence
in an otherwise nonpolar environment, and their conserva-
tion in other REV-ERBb homologues, suggests a functional
role (Figure 8A, Table S1). Ligand -binding speciﬁcity in
many NR ligand-binding pockets often involves hydrogen
bonding between polar group(s) on the ligand and charged
residue(s) of the LBD. The most common polar interaction in
the NR pocket is with an arginine side chain that precisely
orients ligands to ensure speciﬁcity [49]. While this Arg is
conserved in the REV-ERB LBDs, neither it nor any other Arg
residue faces the ligand-binding pocket in the apo or
liganded forms [21]. Glu571, however, is positioned 3.8 A ˚
from the negatively charged propionate groups of heme
(Figure 8A). This is unusual because the carboxy termini of
heme propionate groups usually interact with positively
charged residues such as Arg or Lys [48]. It may be possible
that the negatively charged propionate side chains are
repelled by the acid group of Glu571 in a way that helps to
properly center the heme group, or perhaps helps to
facilitate exchange. Interestingly, in REV-ERBa and E75 the
analogous residue is lysine, which would be predicted to
attract the carboxy termini of the heme molecule, as observed
in other heme-binding proteins.
The other polar residue within close proximity to the heme
group is His381, which is close to the heme coordinating
Cys384 residue, and is highly conserved throughout verte-
brate REV-ERBb homologues (Figure 8A). Given the spectro-
scopic data, which suggest switching of coordinate bonds
from a Cys to a neutral residue such as histidine upon heme
reduction, His381 is a good candidate for this substituting
residue. Indeed coordinate bond switching in other heme
proteins tends to involve nearby residues [33,35]. Interest-
ingly, within this loop there are three other His residues that
Figure 7. The Structure of REV-ERBb LBD in Complex with Fe(III) Heme
(A) Structure of REV-ERBb LBD without [21] and with (B) heme bound in the ligand-binding pocket.
(C) The position of H7 in the apo- (dark blue [21]) and heme-bound (light blue) states of REV-ERBb.
Detailed view of heme-binding site of REV-ERBb LBD in the absence (D) [21] and presence (E) of heme. The core of the protein is in gray, N-terminal part
of H3 (H3’) is in blue and H11 is in green. The side chains of Cys384 and His568 are shown in yellow and heme is colored red.
doi:10.1371/journal.pbio.1000043.g007
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REV-ERB Structure and Gas RegulationFigure 8. Effects of Heme Binding on the REV-ERBb Ligand-Binding Pocket and Co-Repressor Binding Groove
(A) A detailed view of the heme-bound REV-ERBb ligand-binding pocket. Electron density of the porphyrin ring and iron is closely bounded by
hydrophobic sidechains of the ligand-binding pocket.
The hydrophilic propionate groups of heme interact with water molecules (red spheres) near the surface of the protein. Model of Apo-(B) [21] and
heme-bound (C) REV-ERBb LBD structures in complex with a SMRT ID-I co-repressor peptide [101]. Peptide residues (N682–D698) are in dark blue,
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are also within HXXC motifs (Figure S4), which serve as metal
binding sites in the unstructured loops of olfactory receptors
[50] and other hemoproteins. Alternative switching between
these Cys/His residues has the potential to ratchet the loop
peptide along the plane of the heme molecule, and to reshape
the external LBD surface into novel protein interaction sites.
Also worth noting is that the residue next to the
coordinately bound Cys384 is a proline (Pro385). This highly
conserved Cys-Pro duo ﬁts a consensus for ‘‘heme regulatory
motifs,’’ which also include ﬂanking residues such as His, Leu,
Val, Met, Lys, Arg, and Asp [51–53]. This heme regulatory
motif in REV-ERBb includes six of those seven residues
(Figure S4). Such motifs have been shown to be capable of
binding heme reversibly with low micromolar afﬁnity. Muta-
tional analyses of the corresponding prolines in other heme
thiolate proteins suggest that these residues help to direct the
Cys residue toward the heme moiety, as well as to contribute
to the reversibility of Cys-heme binding [54–56]. The
Drosophila E75 LBD is a notable exception to this reversibility,
although this may be explained by the presence of a second
heme binding cysteine (Cys468) that is not ﬂanked by a
proline and has no counterpart in the REV-ERBs [19,30].
A ﬁnal consideration based on this structure is how the
NCOR and SMRT co-repressor peptide-binding site on the
LBD surface changes upon the addition of heme. Heme
binding appears to affect the previously characterized co-
repressor binding site in two ways. First, the hydrophobic
groove becomes broader. Second, helix 11, at the base of the
groove, swings away from the binding site. This ligand-
dependent movement of H11 from the co-repressor binding
site supports the notion that H11 serves as a proxy for the
missing H12, which in other NRs would serve as a platform
for co-repressor binding [21]. Both of these heme-induced
changes are predicted to impact negatively on co-repressor
binding. It is interesting to note that the helices that show the
greatest movement upon heme binding are those that border
the co-repressor binding groove H3–5, H10, and H11 (Figures
7 and 8) [57–60].
A number of speciﬁc REV-ERBb residues are critical for co-
repressor binding, and have been identiﬁed previously [60].
Examples include residues from H11, which are in position to
form a number of critical co-repressor contacts in the apo
form (L572, F575, K576) but that are shifted dramatically in
position by movement of the helix, making them unlikely to
maintain these interactions (Figure 8B, 8C). Likewise in H3,
F409, which has also been identiﬁed as essential [60], shifts
from presumably holding H11 in position for co-repressor
interaction to becoming a hydrophobic contact for heme.
K414 of H3 also appears to make a critical shift that leads to
widening of the hydrophobic peptide-binding groove. At
either end of the hydrophobic groove, there are also charged
residues (K421, R427, and E570) that have been predicted by
modeling to play important roles in anchoring the NCOR
peptide [21]. Two of these three residues, R427 and E570, shift
dramatically away from the co-repressor binding groove in
the heme-bound form (Figure 8B, 8C) [21]. Notably, hydro-
phobic vinyl and methyl groups from the heme moiety also
extend to the surface of the groove close to the region where
H11 was positioned. While this does not appear to provide
interference, it does indicate the possibility for heme to
either interact or interfere with co-repressor binding under
different conditions.
These alterations in the co-repressor binding site are
consistent with the effects of heme on peptide binding in
vitro. Presumably, disruption of one of the coordinating
heme ligands by NO would restore peptide binding by
relieving the strain imposed on the LBD by the hexa-
coordination of heme. Changes to the structure of the
binding site cannot, however, explain why heme and the
presence of NO have the opposite effects in vivo. The answer
to this apparent paradox will most likely require structural
analyses under different conditions, in the presence of other
REV-ERB or co-repressor protein domains, or with other
known or unknown cofactors.
Discussion
A New Heme Binding Fold
Over 20 different protein folds can speciﬁcally bind b-type
heme, which is the most abundant of the hemes and serves as
the functional group for essential proteins such as hemoglo-
bin, myoglobin, and cytochrome b5. Under different evolu-
tionary constraints and pressures, these various heme-
binding folds have adopted additional functional properties,
which include electron transfer, redox sensing, and the
sensing or transport of various gases [48]. The REV-
ERBb381–576/heme structure adds a new and highly dynamic
representative to the heme binding-fold family.
The molecular volume of heme (;520 A ˚ 3) is relatively large
in comparison to most other NR ligands. Hence, the
conformational changes that allow entry and occupancy of
the apo LBD pocket are considerable. Such structural
plasticity has been observed for an increasing number of
NRs (e.g., Ecdysone Receptor [ECR] [61], Liver X Receptor
[LXR] [62], and Estrogen Receptor [ER] [63]). This plasticity is
an important point, as it indicates the potential for other
‘‘orphan’’ receptors, with seemingly inadequate ligand-bind-
ing pockets, and ‘‘constitutive’’ activities, to also be regulated
by novel small molecule ligands within their various natural
in vivo environments.
A Multifunction, Multipurpose Ligand System
As with many other heme-containing proteins, which
include E75 [19], both REV-ERB proteins are also able to
monitor redox state and to bind gases. E75 and the REV-ERBs
are unusual however, in that while discriminating against O2,
they are able to bind both NO and CO gases in vitro.
Although the CO gas responses observed in vivo were much
weaker than those observed for NO, this may be a
consequence of the different methods of gas delivery used,
or differences in the cellular functions and biochemistry of
the two gases.
The different kinetics of gas and heme binding to the REV-
ERB LBDs, and the different rates at which these molecules
groove residues previously identified as being important in peptide binding are in blue (F409, V417, K421, R427, V435, L438, K439) [21,59,60], residues in
H11 are in salmon (which also include residues previously identified as important to co-repressor binding; L572, F575, K576), heme is in red, and other
residues in the groove that shift upon heme binding are in green (K414, Q431).
doi:10.1371/journal.pbio.1000043.g008
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these ligands may have different physiological roles in
different tissues. Gas and redox exchange observed in vitro
occurs within seconds, whereas heme exchange requires many
hours. In the body, changes in redox and gas levels can be
rapid [32,64], whereas heme levels oscillate over hours or days
[42,43]. It may also be of relevance that heme exchange does
not appear to be possible for the ﬂy orthologue E75, such that
the levels of E75 accumulation in the cell are dependent on
the abundance of available heme [19]. Thus, while both E75
and REV-ERB proteins may function as heme sensors, REV-
ERBs appear to have the added ability to function in the
absence of heme.
Although we also attempted to capture the structure of
REV-ERBb in reduced Fe(II) and gas-bound states, and were
able to derive crystals, the latter diffracted poorly due
possibly to the predicted multiplicity of Fe(II) coordinate
bond isoforms (Figure 3). This heterogeneity would be
consistent with our spectroscopic analyses, and those of
Marvin et al. [34], which suggest that the Cys384-heme
coordinate bond is replaced in the Fe(II) population by one
of several alternative neutral donors. It is tempting to
speculate that His381, which is conveniently positioned just
N-terminal to Cys384, may serve as one of these residues. In
fact, the ;133 residue loop between helices 1 and 3 (Figure
S4) contains at least 23 residues that could coordinate heme
(nine His residues, seven Met residues, and seven Cys
residues). This abundance of His, Met, and Cys residues is
around three times their general frequency in the human
proteome. There are also three more histidine residues
(His395, His399, and His475) surrounding the ligand-binding
pocket that could serve as alternate binding partners. If any
of these residues do in fact form alternative coordinate
bonds, this would lead to an additional and unprecedented
number of LBD conformational and functional variants.
Effects of Heme and Gases on Co-Repressor Binding
In terms of how heme and gases affect REV-ERB LBD
functions, our results suggest a major role for both ligands in
co-repressor recruitment. The presence of heme leads to
signiﬁcant broadening of the co-repressor-binding groove
and a highly unfavorable redistribution of interacting
residues, consistent with the dramatic drop in co-repressor
peptide binding observed in vitro. Addition of NO to the
heme-bound LBD reverses the negative effect of heme on
peptide binding, suggesting that NO acts by increasing the
afﬁnity for co-repressor binding. As with heme though, the
effect of NO gas on REV-ERB activity in cultured cells
appears opposite, with, the addition of gas leading to a drop
in the ability of REV-ERB proteins to repress transcription.
This apparent dichotomy in the effects of heme and gas on
co-repressor function in vitro and in vivo cannot yet be
explained by current structural ﬁndings. Structures for
reduced and gas-bound forms of the LBD may help solve
this apparent paradox. On the other hand, the answer may
involve structures of additional parts of the REV-ERB or co-
repressor proteins, or other interacting factors.
While NCOR is an established co-repressor for the REV-
ERBs [65], this study is the ﬁrst to implicate a role for RIP140
as a REV-ERB co-repressor. RIP140 contains ten known NR
interaction motifs, which provide the functional capacity to
interact with different classes of NR partners [66]. Consistent
with a role in REV-ERB modulation, RIP140 has also been
implicated in the regulation of lipid and glucose metabolism
[67]. Furthermore, like the REV-ERBs, its expression is also
induced by retinoic acid [68,69], and it is an important
regulator of skeletal muscle metabolism [70,71]. Hence, this
interaction may have important implications for the study of
cancer and metabolic diseases.
Physiological Roles Implicated by REV-ERB Functions and
Ligands
The evolution of a central circadian clock has allowed
higher eukaryotes to anticipate the daily light and dark cycles,
and to coordinate these with appropriate changes in behavior
and metabolism [72]. As components of the molecular clock,
the REV-ERBs and RORs play important roles in this daily
cycling by regulating clock gene expression in a ligand-
dependent manner. They also play a central role in the
regulation of glucose and lipid metabolism within metabol-
ically intensive tissues [17,73,74]. We propose that the REV-
ERBs coordinate these two different functions by monitoring
the metabolic indicators/signals: heme, NO, and/or CO and
redox.
Heme has long been recognized as an important molecule in
metabolism. It is required for oxygen and carbon dioxide
transport, for cytochrome function in the mitochondria and
for the neutralization of reactive oxygen species arising as a
consequence of metabolism. It is also a required component of
the cytochrome P450s that produce and break down most
lipids, including those that serve as the ligands of most NRs
[23,42,43,48,75–77]. More recently, heme has been shown to
oscillate during the circadian cycle, to inﬂuence the circadian
cycle, and to be a component of the circadian clock proteins
Period 2 (mammalian PER 2 [mPER2]), NPAS2, and now the
REV-ERBs [23,42,43,76,78]. Given that heme is so central to
respiration and other central metabolic processes, and that its
abundance appears to oscillate over time, we suggest that heme
serves as a fundamental measure of the diurnal metabolic state
and as such provides feedback through the REV-ERBs, and
other clock proteins, to entrain the molecular clock.
Further support for this central role of heme is the
reciprocal nature of heme and CO production. Expression
of Aminolevulinate synthase 1 (ALAS1), the rate-limiting
enzyme in heme synthesis, is positively regulated by the clock
complex mPER2/NPAS2/BMAL1, making this expression
circadian in nature. As heme abundance increases, so does
the expression of the heme-regulated enzyme Heme Oxygen-
ase and its product CO. In turn, the presence of CO leads to
dissociation of the mPER2/NPAS2/BMAL1 complex and
down-regulation of Alas1 transcription. Consequently, heme
concentrations fall, and the cycle is reset [8,23,42,79]. As REV-
ERBs also bind heme, their expression is heme dependent
and they repress Bmal1 [6,11,17,20,76], thereby forming a
second reciprocal feed-back loop between heme synthesis
and circadian rhythm.
Heme is also an essential component of the NO and CO
producing enzymes Nitric Oxide Synthetase and Heme
Oxygenase. Not surprisingly, both NO and CO production
have also been shown to oscillate diurnally. In the supra-
chiasmatic nucleus of the hypothalamus, where the central
molecular clock is located, the activity and products of these
enzymes peak during the night [77,80,81]. Given that the
transcriptional activities of NPAS2 [23], REV-ERBa and b
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gases may provide a secondary layer of regulation to the
heme-enriched molecular clock. The membrane permeability
and short half lives of these gases make them ideal neuro-
transmitters [82,83] for communication between the different
nuclear regions of the hypothalamus, where circadian and
metabolic homeostasis are regulated.
The cycling of redox state offers a third potential
mechanism for entrainment of the molecular clock. Redox
homeostasis can be affected by the generation of reactive
oxidant species (ROS), a large proportion of which arise not
surprisingly from mitochondrial respiration. The redox state
of a cell, or organelles, is dependent on the ratio of ROS
generated by metabolic activity and the abundance of
antioxidants, both of which cycle diurnally (reviewed in
[84–86]). Aside from the damage that ROS can cause, these
molecules have become recognized as important signaling
molecules. Interestingly, ROS signaling is commonly associ-
ated with stress response [87], and the hypothalamus controls
the body’s response to stress [88,89]. Considering the redox-
sensing abilities of mPER2 [76], NPAS2 [90], and the REV-
ERBs, it seems likely that both central and peripheral
molecular clocks are also entrained by redox signaling. As
means of entraining circadian rhythm, redox cycling is not
without precedent. It can be traced back to the primordial
biological clock of cyanobacteria, where light and the redox
state, as a measure of metabolism, synchronize the global
transcriptional rhythm of the organism [91].
In summary, our ﬁndings indicate a complex reciprocal
relationship between metabolism and the molecular clock in
which the molecular clock serves to synchronize circadian
metabolic activity [14,17,20,23,33,42,57,73,76,79], and in turn
heme, diatomic gases, and redox serve as local and systemic
indicators of this activity, thereby helping to entrain clocks
within different tissues. Thus, the circadian cycle is not only a
means of metabolic regulation, but is in fact a metabolic cycle
[85].
REV-ERBs in Disease and Treatment
As a whole, the combined ligand set of heme, gases, and
redoxstate,combinedwiththeevengreaternumberofinduced
structural changes in REV-ERB LBDs, provide the potential for
many different protein interactions and physiological func-
tionsthatareinlinewiththecentralrolethattheREV-ERBand
E75 proteins serve in coordinating metabolic processes with
circadiananddevelopmentallytimedevents.Takenfurther,the
rapid responses of REV-ERB proteins to gas signaling, and the
importance of these gas- and REV-ERB-regulated physiological
processes, illustrate the potential for novel, gas-based therapies
for the treatment of related diseases such as mood and sleep-
based disorders, depression, obesity, diabetes, atherosclerosis,
and osteoarthritis.
Methods
Expression constructs. For bacterial expression of the LBD of
REV-ERBa (GenBank [http://www.ncbi.nlm.nih.gov/Genbank] acces-
sion: CAB53540), the construct comprised residues 274–614 with an
internal deletion of residues 324–422. The ﬁrst REV-ERBb (GenBank
accession: CAG33715) construct for bacterial expression comprised
residues 212–579, and the second included residues 241–579, with an
internal deletion of residues 275–357. All constructs were subcloned
into a modiﬁed pET28a vector (Novagen) (GenBank accessions
EF442785 and EF456735).
GAL4 fusion constructs for REV-ERBa and REV-ERBb were
generated by ﬁrst cloning the Gal4 DNA-binding domain (DBD)
(amino acids 1–132) into pBluescript II (Stratagene), containing an
SV40 39UTR. PmeI and NheI restriction sites were introduced as
cloning sites for NR LBD introduction. The following primers were
used to amplify and clone the Rev-erba LBD (aa 215–610; 59-
ATTAGCTAGCATGCTTGCTGAGATGCAGAGTGCC and 39-AT-
TAGTTTAAACCTACTAGTCCACCCGGAAGGACAGCAGC), Rev-
erbb (aa 223–577; 59-ATTAGCTAGCGCCCAGGAACAGCTGCGACC-
CAAGCC and 39-ATTAGTTTAAACCTACTAAACTTTAAAGGC-
CAAGAGCTCC) into pBS Gal1 NheI-PmeI. The Gal4-NR cDNA was
then subcloned into pcDNA 3.1 V5/His using HindIII-PmeI restric-
tion sites.
Protein puriﬁcation and crystallization. Hexahistidine-tagged
proteins were expressed in E. Coli (BL21-Gold[DE3] pLysS; Strata-
gene) grown in 1 l of either Terriﬁc Broth or selenomethionine
medium [92] in the presence of 50 lg/ml kanamycin, 25 lg/ml
chloramphenicol, and in the absence or presence of hemin (12.5 lM;
Sigma. Cells were grown at 37 8Ct oa nO D 600 of 1.2, and, following
the addition of isopropyl-1-thio-D-galactopyranoside (ﬁnal concen-
tration 1 mM) to induce expression, the cells were incubated
overnight with shaking at 25 8C. Following centrifugation, the cell
paste was resuspended in 30 ml binding buffer (5 mM imidazole, 500
mM NaCl, 0.5 mM TCEP, 5% glycerol 50 mM Hepes [pH 7.5]) and
sonicated on ice (3-s intervals) for 5 min. Protein was puriﬁed from
clariﬁed supernatant using Ni-NTA afﬁnity chromatography (column
volume 3 ml). Once loaded, the column was washed with 300 ml of
buffer containing 30 mM imidazole, 500 mM NaCl, 5% glycerol, 0.5
mM TCEP (tris(2-carboxyethyl)phosphine), and 50 mM Hepes (pH
7.5). Protein was eluted from the column using an equivalent buffer
containing 250 mM imidazole, and dialysed overnight into a buffer
containing 500 mM NaCl, 0.5 mM TCEP, and 50 mM Hepes (pH 7.5).
Using hemin supplemented protein, in situ proteolysis of REV-ERBb
(241–579 D 275–357, 17 mg/ml or 212–579, 13.8 mg/ml) was crystal-
lized using the hanging drop vapor diffusion method at 22 8Cb y
mixing 2 ll of the protein solution with 2 ll of the reservoir solution
containing 1.6 M ammonium sulfate, 0.1 M Na Hepes (pH 7.6), 4%
Jeffamine M-600, and was performed in the crystallization drop by
adding a 1:2,000 ratio (w/w) of trypsin (1.5 mg/ml; Sigma) to the
protein [47].
Spectroscopic analysis. Heme-bound REV-ERBb (17 lM) was
reduced to the Fe(II) state using 2 mM dithionite. A CO stock
solution was prepared by saturating degassed storage buffer (10 mM
Tris [pH 8.0] at 4 8C, 500 mM NaCl) with CO (Praxair). Similarly, NO
stock solution was prepared using degassed storage buffer supple-
mented with 200 mM Tris-HCl saturated with NO gas (Aldrich), then
adjusted to (pH 8.0). The estimated concentration of CO and NO in
the stock solutions was 1 mM and 1.9 mM, respectively, based on the
mole fraction solubility of the gases in water [93]. The gases were then
added to the protein samples at a ﬁnal concentration of 100 lM,
providing an approximate 5-fold molar excess of gas in solution.
Removal of heme from receptors. To test dissociation of heme,
heme-bound forms of both REV-ERB LBDs (4 mg) were bound to Ni-
NTA agarose beads (Qiagen) through hexahistidine tags. Proteins
were washed for 12 h at a rate of 1 ml/min using a buffer containing
150 mM NaCl, 10 mM Tris (pH 8.3), 5% glycerol, and 0.1% Triton X-
100. Proteins were eluted from Ni beads using the same buffer
supplemented with 500 mM imidazole. Electronic absorption spectra
were taken of washed and unwashed reference samples at equivalent
protein concentration to compare heme content.
X-ray crystallographic analysis. Data from ﬂash-cooled crystals of
the Se-Met REV-ERBb/heme complex were collected at 0.97 A ˚ at 100
K at the APS at Argonne National Laboratory (SER CAT, beamline
19ID), and the data integrated and scaled to 1.9 A ˚ resolution by using
DENZO/SCALEPACK [94]. The structure was solved by molecular
replacement using the apo REV-ERBb structure (PDB IDs: 2V7C,
2V0V) [21] as a search model using PHASER [95]. Structures were
initially traced by ARP/WARP [96] and then manually rebuilt in
COOT [97]. Final reﬁnement was performed by using REFMAC [98].
Additional crystallographic statistics are given in Table S2. The
drawings were generated with PYMOL [99]. Solvent exposure of heme
in the REV-ERBb structure was calculated using Swiss PDB viewer
[100]. Heme volume calculations were made using the Java molecular
editor (Peter Ertl, Novartis) using the smiles descriptors: Heme, CC1
¼ C(C2 ¼ CC3 ¼ C(C(¼ C([N]3)C¼ C4C(¼ C(C(¼ N4) C ¼ C5C(¼ C(C(¼
N5)C ¼ C1[N]2) C ¼ C)C)C ¼ C) C)C)CCC(¼ O)O)CCC(¼ O)O.[Feþ3]
(NCBI Pubchem). Modeling of the SMRT co-repressor motif with
both REV-ERB structures was done using PYMOL. REV-ERB/SMRT
models were generated by structural alignment of the REV-ERB
structures (PDB IDs: 2V0V, [21]; 3CQV) with the structure of
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1KKQ, [101]). The structure of the PPARa LBD and antagonist were
then removed, leaving the model of each REV-ERB structure with the
SMRT co-repressor motif.
Cell culture and treatments. HEK 293T and HepG2 cells were
grown in Dulbecco’s modiﬁed Eagle’s medium (Wisent) supplemented
with 10% fetal bovine serum (Sigma), 2 mM L-glutamine, 100 IU/ml
penicillin, 0.1 mg/ml streptomycin, and nonessential amino acids
(Invitrogen). Cells were incubated at 37 8Ci n5 %C O 2 and, upon
harvest, washed with PBS (Wisent). Gas treatment of cells was
performed in the presence of 25 lM Hemin (Sigma) and used the
NO donors Deta/NO (300 lM, Sigma) freshly dissolved in 10 mM
NaOH, or two doses of SNAP (200 lM, Sigma), dissolved in 5 mM
EDTA and 10 mM PBS, separated by 5 h. CO treatment of cells was
done by culturing cells in sealed chambers with 5% CO2 and 0.05%
(500 ppm) 0.2% (2,000 ppm) CO (Praxair) at 37 8C. Prior to transfer
of cells to chambers, culture medium was spiked with a volume of
CO-saturated buffer equivalent to their respective treatment
concentration. All experiments were conducted a minimum of three
times in triplicate, and the mean þ/  standard deviation of a
representative experiment is shown.
Luciferase-LBD reporter assays. Using antibiotic free medium,
293T cells were seeded at a density of 2310
5 cells per well in 24-well
plates 1 d prior to transfection. Transfection was carried out using
Lipofectamine 2000 (Invitrogen) as described in the manufacture’s
instructions. Unless otherwise stated, transfections contained 400 ng
of 2X-UAS luciferase reporter, 50 ng pSV40 b-gal, 50 ng of either
Rev-erba-Gal4 or Rev-erbb-Gal4 and pSP empty vector to a total of
800 ng DNA per well. REV-ERBa-GAL4 and REV-ERBb-GAL4 were
expressed using the modiﬁed pcDNA 3.1 plasmid described above;
NCOR, luciferase, and b-GAL constructs were expressed as previously
described [102,103]; and the pI RIP140 was a kind gift from M.G.
Parker. Compound treatments were applied 6 h post-transfection as
described above and cells harvested 24 h later. Luciferase values were
normalized to b-GAL activities as described previously and are
presented as a ratio of the reporter alone under equivalent
conditions [19]. In the case of Deta/NO treatments, luciferase values
were also normalized to GAL4 only reporter controls.
RNA interference assay. HEK 293T cells were transfected with
siRNA using Lipofectamine 2000 (Invitrogen) according to the
manufacturer’s protocol. For each targeted gene, a pool of four
siRNAs (Dharmacon) with the following sequences were used. Rev-
erba: GCAUGGACGCAGUGGGCGAUU, GGGCAUGUCUCGA-
GACGCUUU, CGGCAGGGCAACUCAAAGAUU, GGGCGAACG-
GUGCAGGAGAUU; Rev-erbb: GAAGAAUGAUC GAAUAGAUUU,
GAACAUGGAGCAAUAUAAUUU, GAGGAGCUCUUGGC-
CUUUAUU, and UAAAC AACAUGCACUCUGAUU. Experimental
treatments were completed between 24 h and 96 h of siRNA
transfection.
Quantitative Real Time-PCR. Total RNA was isolated from 1 to 2.5
3 10
6 cells using the RNeasy mini kit (Qiagen) according to
manufacturer’s protocol. 2 lg RNA samples were individually treated
with DNase I (Fermentas) and then reverse-transcribed to synthesize
cDNA using pd(N)6-random hexamer primers (Promega) and
RevertAid H Minus M-MuLV Reverse Transcriptase (Fermentas).
Quantitative PCR was performed in triplicate for each sample with
SYBR Green (Sigma) using the ABI Prism 7000 sequence detection
system (Applied Biosystems). Transcript levels were determined using
the comparative Ct method with b-actin as reference. Primer
sequences used were as follows: Rev-erba, forward, ACTTCCCAC-
CATCCCCCACT, reverse, GGAAGAAGGGGAGCCGTCAT [15]; Rev-
erbb, forward, TCTTGTCACAGTGAGGGTTCT, reverse, GCGAGAT-
CACCATTCTTGGGA; Bmal1, forward, GAAAAGCGGCGTCGGGA-
TAA, reverse, GGACATTGCGTTGCATGTTGG [104]; and b-actin,
forward, TGGACTTCGAGCAAGAGATGG, reverse, GGAAG-
GAAGGCTGGAAGAGTG [105].
Fluorescence polarization. Using the puriﬁed REV-ERB LDB
constructs, peptide interaction was monitored using ﬂuorescence
polarization. N-terminally ﬂuorescein-labeled peptides, correspond-
ing to interaction domain I for NCOR (110 nM; DPASNLGLEDIIR-
KALMGSF) and SMRT (110 nM; ASTNMGLEAIIRKALMGKYD), were
combined with a dilution series of either LBD in a buffer of 100 mM
Tris (pH 8.2) and 150 mM NaCl. Bacterial expression of the LBDs was
done in the presence or absence of supplemental heme, as described
above, resulting in either apo- or holo-forms of the receptors. Gas
treatment of solutions was done using the NO donor SNAP (1,200
lM). Detection of changes in polarization was measured using a
Biotek Synergy 2 plate reader (kexcitation¼485 nm, kemission¼528 nm)
in 384-well format using black PCR microplates (Axygen). Fluores-
cence polarization, in millipolarization (mP) units, was calculated as
mP ¼ (I   I?)/( Iþ I?) 3 1,000 where I ¼ parallel emission intensity
measurement and I? ¼ perpendicular emission intensity measure-
ment. Increases in mP units reﬂect increased binding of the peptide
to the REV-ERB LBDs. Measurements in graphs are in triplicate and
represent a single time point during a 5-h incubation. Binding
parameters were calculated by nonlinear curve ﬁtting using the one
site binding (hyperbola) formula Y ¼ Bmax 3 X/(Kd þ X) (GraphPad
Prism version 4.0 for window, GraphPad Software).
Supporting Information
Figure S1. Bacterial Expressed and Puriﬁed REV-ERBa and b LBDs
Increased supplementation of bacterial cultures with hemin leads to
greater heme occupancy with no effect on stability. (A) REV-ERBa
and (B) REV-ERBb LBDs after recombinant expression and puriﬁca-
tion with Ni afﬁnity resin. Lane 1, no supplementation; lane 2,
[hemin] ¼ 0.05 lM; lane 3, [hemin] ¼ 0.20 lM; lane 4, [hemin] ¼ 0.40
lM.
Found at doi:10.1371/journal.pbio.1000043.sg001 (3.43 MB TIF).
Figure S2. Washing of Heme-Bound REV-ERBa (A) and b (B) LBDs
Leads to Depletion of Heme Occupancy
At equal protein concentration (280 nm), electronic absorption
spectra for washed REV-ERB LBDs show a reduction in the
characteristic hemoprotein c peak (413 nm).
Found at doi:10.1371/journal.pbio.1000043.sg002 (293 KB TIF).
Figure S3. Quantitative Real-Time PCR Analysis of Bmal1 and Rev-
erba and b Transcript Levels in HepG2 Cells
Endogenous mRNA levels of Bmal1 and Rev-erba and b under
control and 300 lM Deta/NO treatments.
Found at doi:10.1371/journal.pbio.1000043.sg003 (53 KB TIF).
Figure S4. Sequence Alignment of Human REV-ERBa, Human REV-
ERBb, and REV-ERBb Homologues in Other Metazoans
Sequences were aligned using Clustal W [106] and then adjusted
manually. Determined secondary structure of heme-bound REV-
ERBb is labeled above and residues involved in heme coordination
are marked (*). All residues that could coordinate heme in the loop
and His, Cys through the proteins are in bold type. Dashed line, Cys/
Pro motifs of putative heme responsive motifs; solid line, HXXC
motifs.
Found at doi:10.1371/journal.pbio.1000043.sg004 (177 KB TIF).
Table S1. Residues within 4 A ˚ of Heme in REV-ERBb Structure
Residues have been categorized based on whether they interaction
with the heme face or heme edge. The table lists position, distance
from heme, chemical property, and hydropathy index for each
residue [107].
Found at doi:10.1371/journal.pbio.1000043.st001 (487 KB TIF).
Table S2. Data Collection and Solution Structure Parameters
Found at doi:10.1371/journal.pbio.1000043.st002 (38 KB DOC).
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